Book Value Per Share (mrq):2.08 Cash Value Per Share (mrq):1.32
52 Week High $30.00
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. The Company is currently focused on developing picoplatin, a new and differentiated platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration. Poniard is headquartered in San Francisco, CA and has an office in Seattle, Washington. Poniard is traded on the NASDAQ Global Market under the symbol PARD. http://www.poniard.com/
November 18, 2011 – Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced today that it has entered into a licensing agreement with an undisclosed party for rights to Poniard’s focal adhesion kinase (FAK) technology, including a preclinical candidate that is a selective small molecule inhibitor of FAK. Under terms of the agreement, Poniard granted the licensee worldwide rights for the development and commercialization of any FAK-related products, including the preclinical candidate, in exchange for an upfront cash payment of $250,000, milestone payments and other considerations, as well as royalty payments on net sales of any products covered by the license. The licensee is responsible for all costs related to further development and commercialization. Also known as protein tyrosine kinase 2 (PTK2), FAK is associated with the invasion and metastasis of tumor cells. Inhibition of FAK activity is thought to decrease the mobility of certain cancer cells, reducing the potential for metastases. FAK is also thought to play a role in tumor formation and progression. Poniard’s FAK technology was developed through a research funding agreement with The Scripps Research Institute. “Poniard’s FAK technology includes novel inhibitors against a pathway which plays a potentially critical role in the proliferation of cancer,” said Ronald A. Martell, chief executive officer of Poniard. “Our discovery and early research efforts in this area began in 2005 under a funded research agreement with the Scripps Research Institute.